Two Sigma Securities’s Outlook Therapeutics OTLK Stock Holding History

Two Sigma Securities’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-35,664	Closed	-$37.8K	–	1870
2025 Q3	$37.8K	Buy	+35,664	New	+$61.7K	0.01%	1028
2023 Q4	–	Sell	-792	Closed	-$3.5K	–	3436
2023 Q3	$3.5K	Buy	792 +167	+27%	+$3.69K	﹤0.01%	2808
2023 Q2	$21.7K	Buy	+625	New	+$17K	﹤0.01%	2495
2021 Q2	–	Sell	-622	Closed	-$28K	–	1648
2021 Q1	$28K	Buy	+622	New	+$23.8K	﹤0.01%	763
2018 Q4	–	Sell	-115	Closed	-$18K	–	2654
2018 Q3	$18K	Sell	115 -28	-20%	-$3.94K	﹤0.01%	2457
2018 Q2	$19K	Sell	143 -1	-0.7%	-$147	﹤0.01%	2562
2018 Q1	$21K	Sell	144 -103	-42%	-$18.4K	﹤0.01%	2574
2017 Q4	$51K	Buy	247 +173	+234%	+$35.9K	﹤0.01%	1524
2017 Q3	$16K	Buy	+74	New	+$13.5K	﹤0.01%	843

Other funds holding OTLK

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GWM

Gilpin Wealth Management Denver, Colorado $126M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Securities's OTLK Position: Q4 2025 in Review

Two Sigma Securities sold out of Outlook Therapeutics (OTLK) in Q4 2025, closing a stake of 35,664 shares — an estimated $37.8K sold.

Two Sigma Securities first reported a position in OTLK in Q3 2017 and held it in 9 quarters. The position peaked at $51K in Q4 2017. 53 funds tracked by Wall St. Rank hold OTLK as of Q4 2025.

Two Sigma Securities reported no remaining Outlook Therapeutics position as of Q4 2025 after selling out during the quarter.
Two Sigma Securities sold 35,664 Outlook Therapeutics shares in Q4 2025, an estimated $37.8K.
Two Sigma Securities first reported a position in Outlook Therapeutics in Q3 2017 and held it in 9 quarters.
Two Sigma Securities's Outlook Therapeutics position peaked at $51K in Q4 2017.
53 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2025.

Based on Two Sigma Securities's 13F filing for Q4 2025, filed 17 Feb 2026.